DTCs from EGFR‐mutant NSCLC cells treated with EGFR inhibitors display apoptosis suppression and they become sensitive to the treatment with EGFR inhibitors in combination with navitoclax (ABT293), a BCL‐x, and BCL2 inhibitor.47 This evidence concerns the gene EGFR and non-small cell lung carcinoma.